SEARCH:   Advanced

Blood, 15 April 2004, Vol. 103, No. 8, pp. 3148-3157. Prepublished online as a Blood First Edition Paper on December 4, 2003; DOI 10.1182/blood-2003-06-1984. This Article Full Text (PDF) All Versions of this Article: 2003-06-1984v1 103/8/3148    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Moreaux, J. Articles by Tarte, K. Search for Related Content PubMed PubMed Citation Articles by Moreaux, J. Articles by Tarte, K. Social Bookmarking                   What's this? Submitted June 18, 2003 Accepted December 1, 2003 BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone Jerome Moreaux, Eric Legouffe, Eric Jourdan, Philippe Quittet, Thierry Reme, Cecile Lugagne, Philippe Moine, Jean-Francois Rossi, Bernard Klein*, and Karin Tarte INSERM, Unite 475, and CHU Montpellier, Montpellier, France Service de Medecine Interne B, CHU Nimes, Nimes, France * Corresponding author; email: klein{at}montp.inserm.fr. Identification of growth factors in neoplasias may be a target for future therapies by blocking either growth factor-receptor interaction or the induced pathway. Using gene expression profiling, we identified overexpression of two receptors for APRIL and BAFF in malignant plasma cells compared to normal plasma cells. APRIL and BAFF are involved in a variety of tumor and autoimmune diseases, including B-cell malignancies. We confirmed the expression of BAFF and APRIL receptors (BCMA, TACI and BAFF-R) in a majority of 13 myeloma cell lines and in the purified primary myeloma cells of 11 patients. APRIL and BAFF were potent survival factors for exogenous cytokine-dependent myeloma cell lines and were autocrine growth factors for the RPMI8226 and L363 autonomously growing cell lines. These factors activated NF-B, PI-3 kinase/AKT and MAPK kinase pathways and induced a strong upregulation of the Mcl-1 and Bcl-2 anti-apoptotic proteins in myeloma cells. BAFF or APRIL was also involved in the survival of primary myeloma cells cultured with their bone-marrow environment and protected them from DEX-induced apoptosis. Finally, serum levels of BAFF and APRIL were increased about five fold in patients with MM as compared to healthy donors. Altogether, these data suggest that APRIL/BAFF inhibitors may be of clinical value in MM. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. S. Kim, J.-Y. Park, I. Jou, and S. M. Park Functional implication of BAFF synthesis and release in gangliosides-stimulated microglia J. Leukoc. Biol., August 1, 2009; 86(2): 349 - 359. [Abstract] [Full Text] [PDF] A. J. Novak, S. L. Slager, Z. S. Fredericksen, A. H. Wang, M. M. Manske, S. Ziesmer, M. Liebow, W. R. Macon, S. R. Dillon, T. E. Witzig, et al. Genetic Variation in B-Cell-Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma Cancer Res., May 15, 2009; 69(10): 4217 - 4224. [Abstract] [Full Text] [PDF] A. C. Sprynski, D. Hose, L. Caillot, T. Reme, J. D. Shaughnessy Jr, B. Barlogie, A. Seckinger, J. Moreaux, M. Hundemer, M. Jourdan, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor Blood, May 7, 2009; 113(19): 4614 - 4626. [Abstract] [Full Text] [PDF] F. C. Kimberley, L. van Bostelen, K. Cameron, G. Hardenberg, J. A. Marquart, M. Hahne, and J. P. Medema The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking FASEB J, May 1, 2009; 23(5): 1584 - 1595. [Abstract] [Full Text] [PDF] B. Sung, A. B. Kunnumakkara, G. Sethi, P. Anand, S. Guha, and B. B. Aggarwal Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model Mol. Cancer Ther., April 1, 2009; 8(4): 959 - 970. [Abstract] [Full Text] [PDF] J. A. Burger, M. P. Quiroga, E. Hartmann, A. Burkle, W. G. Wierda, M. J. Keating, and A. Rosenwald High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation Blood, March 26, 2009; 113(13): 3050 - 3058. [Abstract] [Full Text] [PDF] D-A Landau, M Rosenzwajg, D Saadoun, D Klatzmann, and P Cacoub The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders Ann Rheum Dis, March 1, 2009; 68(3): 337 - 344. [Abstract] [Full Text] [PDF] E. Mohr, K. Serre, R. A. Manz, A. F. Cunningham, M. Khan, D. L. Hardie, R. Bird, and I. C. M. MacLennan Dendritic Cells and Monocyte/Macrophages That Create the IL-6/APRIL-Rich Lymph Node Microenvironments Where Plasmablasts Mature J. Immunol., February 15, 2009; 182(4): 2113 - 2123. [Abstract] [Full Text] [PDF] D. Bonci, M. Musumeci, V. Coppola, A. Addario, C. Conticello, M. Hahne, M. Gulisano, F. Grignani, and R. De Maria Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity Haematologica, December 1, 2008; 93(12): 1899 - 1902. [Abstract] [Full Text] [PDF] S.-H. Kuo, P.-Y. Yeh, L.-T. Chen, M.-S. Wu, C.-W. Lin, K.-H. Yeh, Y.-S. Tzeng, J.-Y. Chen, P.-N. Hsu, J.-T. Lin, et al. Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma Blood, October 1, 2008; 112(7): 2927 - 2934. [Abstract] [Full Text] [PDF] A. Geffroy-Luseau, G. Jego, R. Bataille, L. Campion, and C. Pellat-Deceunynck Osteoclasts support the survival of human plasma cells in vitro Int. Immunol., June 1, 2008; 20(6): 775 - 782. [Abstract] [Full Text] [PDF] I. Nestorov, A. Munafo, O. Papasouliotis, and J. Visich Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis J. Clin. Pharmacol., April 1, 2008; 48(4): 406 - 417. [Abstract] [Full Text] [PDF] E. Belnoue, M. Pihlgren, T. L. McGaha, C. Tougne, A.-F. Rochat, C. Bossen, P. Schneider, B. Huard, P.-H. Lambert, and C.-A. Siegrist APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells Blood, March 1, 2008; 111(5): 2755 - 2764. [Abstract] [Full Text] [PDF] U.-M. Fagerli, R. U. Holt, T. Holien, T. K. Vaatsveen, F. Zhan, K. W. Egeberg, B. Barlogie, A. Waage, H. Aarset, H. Y. Dai, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells Blood, January 15, 2008; 111(2): 806 - 815. [Abstract] [Full Text] [PDF] R. T. Woodland, C. J. Fox, M. R. Schmidt, P. S. Hammerman, J. T. Opferman, S. J. Korsmeyer, D. M. Hilbert, and C. B. Thompson Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival Blood, January 15, 2008; 111(2): 750 - 760. [Abstract] [Full Text] [PDF] K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications Clin. Cancer Res., December 15, 2007; 13(24): 7289 - 7295. [Abstract] [Full Text] [PDF] A. Kukreja, A. Hutchinson, K. Dhodapkar, A. Mazumder, D. Vesole, R. Angitapalli, S. Jagannath, and M. V. Dhodapkar Enhancement of clonogenicity of human multiple myeloma by dendritic cells J. Exp. Med., August 7, 2006; 203(8): 1859 - 1865. [Abstract] [Full Text] [PDF] Y.-T. Tai, X.-F. Li, I. Breitkreutz, W. Song, P. Neri, L. Catley, K. Podar, T. Hideshima, D. Chauhan, N. Raje, et al. Role of B-Cell-Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment. Cancer Res., July 1, 2006; 66(13): 6675 - 6682. [Abstract] [Full Text] [PDF] L. Fu, Y.-C. Lin-Lee, L. V. Pham, A. Tamayo, L. Yoshimura, and R. J. Ford Constitutive NF-{kappa}B and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas Blood, June 1, 2006; 107(11): 4540 - 4548. [Abstract] [Full Text] [PDF] T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells Blood, May 15, 2006; 107(10): 4053 - 4062. [Abstract] [Full Text] [PDF] D. Bischof, S. F. Elsawa, G. Mantchev, J. Yoon, G. E. Michels, A. Nilson, S. L. Sutor, J. L. Platt, S. M. Ansell, G. von Bulow, et al. Selective activation of TACI by syndecan-2 Blood, April 15, 2006; 107(8): 3235 - 3242. [Abstract] [Full Text] [PDF] S. F. Elsawa, A. J. Novak, D. M. Grote, S. C. Ziesmer, T. E. Witzig, R. A. Kyle, S. R. Dillon, B. Harder, J. A. Gross, and S. M. Ansell B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia Blood, April 1, 2006; 107(7): 2882 - 2888. [Abstract] [Full Text] [PDF] T. Matsumoto and M. Abe Myeloma-Bone Interaction: A Vicious Cycle IBMS BoneKEy, March 1, 2006; 3(3): 8 - 14. [Abstract] [Full Text] [PDF] M. Yang, H. Hase, D. Legarda-Addison, L. Varughese, B. Seed, and A. T. Ting B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells J. Immunol., September 1, 2005; 175(5): 2814 - 2824. [Abstract] [Full Text] [PDF] J. Shaughnessy Jr APRIL showers cause CLL and myeloma to flower Blood, August 1, 2005; 106(3): 766 - 767. [Full Text] [PDF] J. Moreaux, F. W. Cremer, T. Reme, M. Raab, K. Mahtouk, P. Kaukel, V. Pantesco, J. De Vos, E. Jourdan, A. Jauch, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature Blood, August 1, 2005; 106(3): 1021 - 1030. [Abstract] [Full Text] [PDF] G. P. Sims, R. Ettinger, Y. Shirota, C. H. Yarboro, G. G. Illei, and P. E. Lipsky Identification and characterization of circulating human transitional B cells Blood, June 1, 2005; 105(11): 4390 - 4398. [Abstract] [Full Text] [PDF] K. Ingold, A. Zumsteg, A. Tardivel, B. Huard, Q.-G. Steiner, T. G. Cachero, F. Qiang, L. Gorelik, S. L. Kalled, H. Acha-Orbea, et al. Identification of proteoglycans as the APRIL-specific binding partners J. Exp. Med., April 25, 2005; (2005) jem.20042309. [Abstract] [Full Text] [PDF] T. Sanda, S. Iida, H. Ogura, K. Asamitsu, T. Murata, K. B. Bacon, R. Ueda, and T. Okamoto Growth Inhibition of Multiple Myeloma Cells by a Novel I{kappa}B Kinase Inhibitor Clin. Cancer Res., March 1, 2005; 11(5): 1974 - 1982. [Abstract] [Full Text] [PDF] P. Scapini, A. Carletto, B. Nardelli, F. Calzetti, V. Roschke, F. Merigo, N. Tamassia, S. Pieropan, D. Biasi, A. Sbarbati, et al. Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases Blood, January 15, 2005; 105(2): 830 - 837. [Abstract] [Full Text] [PDF] A. J. Novak, D. M. Grote, M. Stenson, S. C. Ziesmer, T. E. Witzig, T. M. Habermann, B. Harder, K. M. Ristow, R. J. Bram, D. F. Jelinek, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome Blood, October 15, 2004; 104(8): 2247 - 2253. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020